Enavogliflozin/Metformin Hydrochloride

依那格列净/盐酸二甲双胍

Report date: 2024/06/27 17:16:16

Base Information

Drug NameEnavogliflozin/Metformin Hydrochloride
Drug Alias NameEnavogliflozin/metformin hydrochlorideEnvlomet SRDWJ-1525
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2023/07/19
Country/TerritoryUnited StatesSouth Korea
CombinationsYes EnavogliflozinMetformin Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDaewoong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A